Overview

The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia

Status:
Not yet recruiting

Trial end date:
2024-02-28

Target enrollment:

Participant gender:

Summary

A randomized, open-label, multicenter study to compare the efficacy and safety of terbutaline plus danazol compared to danazol monotherapy for the second-line treatment of adults with corticosteroid-resistant or relapsed primary immune thrombocytopenia (ITP).

Phase:

Phase 2

Details

Lead Sponsor:

Peking University People's Hospital

Treatments:

Danazol
Terbutaline